{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:44:29Z","timestamp":1790729069887,"version":"4.1.0"},"reference-count":173,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["Z01 HL-06193"],"award-info":[{"award-number":["Z01 HL-06193"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["U01-AI119125"],"award-info":[{"award-number":["U01-AI119125"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jid.2021.02.743","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T18:40:13Z","timestamp":1618857613000},"page":"2328-2337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["New Frontiers in Psoriatic Disease Research,\u00a0Part II: Comorbidities and Targeted Therapies"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1338-9847","authenticated-orcid":false,"given":"Di","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7750-910X","authenticated-orcid":false,"given":"Amit K.","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3320-3686","authenticated-orcid":false,"given":"Rachel S.","family":"Golpanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7930-9964","authenticated-orcid":false,"given":"Samuel T.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-5130","authenticated-orcid":false,"given":"Nehal N.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2443-153X","authenticated-orcid":false,"given":"Bridget","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9416-1152","authenticated-orcid":false,"given":"Zhen-rui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-1822","authenticated-orcid":false,"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-567X","authenticated-orcid":false,"given":"Stacie","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7883-6439","authenticated-orcid":false,"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.02.743_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jid.2021.02.743_bib2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/jdv.13152","article-title":"Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study","volume":"30","author":"Ahlehoff","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.02.743_bib3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jid.2021.02.743_bib4","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jaad.2015.02.1095","article-title":"Psoriasis and risk of diabetes-associated microvascular and macrovascular complications","volume":"72","author":"Armstrong","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib6","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003\u20132011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/archdermatol.2012.1401","article-title":"Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis","volume":"148","author":"Azfar","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib8","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jid.2017.02.977","article-title":"TNF-\u03b1 antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study","volume":"137","author":"Bissonnette","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2016.02.1164","volume":"75","author":"Bissonnette","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib151","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib152","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/jid.2015.144","article-title":"Interleukin-23\/interleukin-17A dysfunction phenotypes inform possible clinical effects from anti-interleukin-17A therapies","volume":"135","author":"Blauvelt","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib10","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jid.2021.02.743_bib153","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib154","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis (IMMhance): a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib155","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study","volume":"83","author":"Blauvelt","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1468-3083.2010.03947.x","article-title":"Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study","volume":"25","author":"Boehncke","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.02.743_bib12","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1365-2133.2008.08814.x","article-title":"Psoriasis and the risk of incident diabetes mellitus: a population-based study","volume":"159","author":"Brauchli","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib13","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1365-2133.2008.09020.x","article-title":"Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis","volume":"160","author":"Brauchli","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib14","first-page":"1","article-title":"Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: infection risk and patient counseling in uncertain times","volume":"10","author":"Brownstone","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2021.02.743_bib15","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1365-2133.2008.08742.x","article-title":"Serum leptin levels, skin leptin and leptin receptor expression in psoriasis","volume":"159","author":"Cerman","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib16","first-page":"1","article-title":"Liraglutide improved inflammation via mediating IL-23\/Th-17 pathway in obese diabetic mice with psoriasiform skin","author":"Chen","year":"2020","journal-title":"J\u00a0Dermatol Treat"},{"key":"10.1016\/j.jid.2021.02.743_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamadermatol.2015.3605","article-title":"Psoriasis and the risk of depression in the US population: national health and nutrition examination survey 2009\u20132012","volume":"152","author":"Cohen","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.intimp.2018.06.020","article-title":"Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials [published correction appears in Int Immunopharmacol 2018;64:432]","volume":"62","author":"Cui","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jid.2021.02.743_bib19","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A\u00a0phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jid.2021.02.743_bib20","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions [published correction appears in J Invest Dermatol 2010;130:2517]","volume":"130","author":"Davidovici","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamacardio.2017.1213","article-title":"Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography\/computed tomography","volume":"2","author":"Dey","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jid.2021.02.743_bib22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1161\/ATVBAHA.110.214585","article-title":"Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-alpha blockers and traditional disease-modifying antirheumatic drugs","volume":"31","author":"Di Minno","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jid.2021.02.743_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2340\/00015555-0510","article-title":"Psoriasis and dyslipidaemia: a population-based study","volume":"88","author":"Dreiher","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2021.02.743_bib24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/annrheumdis-2012-201497","article-title":"The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone","volume":"72","author":"Eder","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2021.02.743_bib25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/art.40366","article-title":"TNF-alpha inhibitors are associated with reduced indices of subclinical atherosclerosis in patients with psoriatic disease","volume":"70","author":"Eder","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2021.02.743_bib26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2019.04.042","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy [published correction appears in J Am Acad Dermatol 2020;82:780]","volume":"81","author":"Elmets","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib28","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jid.2021.02.743_bib29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamacardio.2019.2589","article-title":"Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index","volume":"4","author":"Elnabawi","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jid.2021.02.743_bib30","doi-asserted-by":"crossref","first-page":"101047","DOI":"10.1016\/j.molmet.2020.101047","article-title":"Psoriatic skin inflammation induces a pre-diabetic phenotype via the endocrine actions of skin secretome","volume":"41","author":"Evans","year":"2020","journal-title":"Mol Metab"},{"key":"10.1016\/j.jid.2021.02.743_bib31","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.02.743_bib32","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/jdv.13891","article-title":"The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials","volume":"31","author":"Fleming","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.02.743_bib33","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: Phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib34","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S2665-9913(20)30169-7","article-title":"COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case\u2013control study","volume":"2","author":"Fredi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jid.2021.02.743_bib35","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2018.08.025","article-title":"Differential efficacy of biologic treatments targeting the TNF-\u03b1\/IL-23\/IL-17 axis in psoriasis and psoriatic arthritis","volume":"111","author":"Furue","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.jid.2021.02.743_bib36","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jaad.2020.09.001","article-title":"National Psoriasis Foundation COVID-19 Task Force Guidance for management of psoriatic disease during the pandemic: version 1","volume":"83","author":"Gelfand","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National Psoriasis Foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 2 - advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments [e-pub ahead of print]","author":"Gelfand","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib38","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/jid.2010.12","article-title":"Psoriasis and cardiovascular risk: strength in numbers","volume":"130","author":"Gelfand","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib39","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/jid.2011.32","article-title":"Psoriasis and cardiovascular risk: strength in numbers, part II","volume":"131","author":"Gelfand","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib40","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2021.02.743_bib41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A\u00a0Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib42","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A\u00a0randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib43","first-page":"697","article-title":"A\u00a0phase IV, randomised, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial)","volume":"66","author":"Gelfand","year":"2018","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.jid.2021.02.743_bib44","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","article-title":"The risk of mortality in patients with psoriasis: results from a population-based study","volume":"143","author":"Gelfand","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib45","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.02.743_bib46","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.clinthera.2020.01.025","article-title":"Effects of stress on itch","volume":"42","author":"Golpanian","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.jid.2021.02.743_bib156","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2021.02.743_bib47","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/jdv.15012","article-title":"Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study","volume":"32","author":"Gordon","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.02.743_bib157","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.02.743_bib158","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib48","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"Greb","year":"2016","journal-title":"Psoriasis. Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2021.02.743_bib159","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.02.743_bib49","first-page":"e1082","volume":"139","author":"Grundy","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jid.2021.02.743_bib50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/jcb.21080","article-title":"Long-term effects of tumor necrosis factor-alpha treatment on insulin signaling pathway in HepG2 cells and HepG2 cells overexpressing constitutively active Akt\/PKB","volume":"100","author":"Gupta","year":"2007","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.jid.2021.02.743_bib51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.smrv.2015.09.003","article-title":"Psoriasis and sleep disorders: a systematic review","volume":"29","author":"Gupta","year":"2016","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.jid.2021.02.743_bib52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMc2009567","article-title":"COVID-19 in immune-mediated inflammatory diseases - case series from New York","volume":"383","author":"Haberman","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.02.743_bib53","doi-asserted-by":"crossref","first-page":"H867","DOI":"10.1152\/ajpheart.00774.2016","article-title":"Psoriasis as a human model of disease to study inflammatory atherogenesis","volume":"312","author":"Harrington","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jid.2021.02.743_bib160","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2021.02.743_bib54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00403-019-01998-7","article-title":"Pruritus and sleep disturbances in patients with psoriasis","volume":"312","author":"Hawro","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2021.02.743_bib55","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bjd.15149","article-title":"Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis","volume":"176","author":"Hjuler","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib56","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1194\/jlr.M027367","article-title":"Psoriasis alters HDL composition and cholesterol efflux capacity","volume":"53","author":"Holzer","year":"2012","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jid.2021.02.743_bib57","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.3390\/ijms18102211","article-title":"Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment","volume":"18","author":"Hu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2021.02.743_bib58","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/ced.12582","article-title":"The impact of psychosocial stress on healthy skin","volume":"40","author":"Hunter","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib59","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.006283","article-title":"Lowering interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor-a antagonism or cyclosporine in psoriasis","volume":"10","author":"Ikonomidis","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jid.2021.02.743_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000472149","article-title":"Glycemic control in the treatment of psoriasis","volume":"233","author":"Ip","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2021.02.743_bib61","doi-asserted-by":"crossref","first-page":"e13100","DOI":"10.1111\/dth.13100","article-title":"Effects of family constellation seminars on itch in patients with atopic dermatitis and psoriasis: a patient preference controlled trial","volume":"32","author":"Jafferany","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2021.02.743_bib62","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/jmri.24832","article-title":"Investigation of the pruritus-induced functional activity in the rat brain using manganese-enhanced MRI","volume":"42","author":"Jeong","year":"2015","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.jid.2021.02.743_bib63","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jamacardio.2018.2769","article-title":"Association between aortic vascular inflammation and coronary artery plaque characteristics in psoriasis","volume":"3","author":"Joshi","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jid.2021.02.743_bib64","article-title":"Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors [e-pub ahead of print]","author":"Jovani","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2021.02.743_bib65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2340\/00015555-3065","article-title":"Influence of itch and pain on sleep quality in atopic dermatitis and psoriasis","volume":"99","author":"Kaaz","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2021.02.743_bib66","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2021.02.743_bib67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: which therapy for which patient: focus on special populations and chronic infections","volume":"80","author":"Kaushik","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib68","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2021.02.743_bib69","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jid.2021.02.743_bib70","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/dc12-2330","article-title":"Psoriasis and new-onset diabetes: a Danish nationwide cohort study","volume":"36","author":"Khalid","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jid.2021.02.743_bib71","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jaad.2018.03.011","article-title":"Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: feasibility study using 18F-fluorodeoxyglucose PET\/CT","volume":"80","author":"Kim","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib72","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.amjmed.2009.08.022","article-title":"Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis","volume":"123","author":"Kimball","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jid.2021.02.743_bib73","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2340\/00015555-2801","article-title":"Long-term impact of ixekizumab on psoriasis itch severity: results from a phase III clinical trial and long-term extension","volume":"98","author":"Kimball","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2021.02.743_bib74","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2011.06.035","article-title":"Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis","volume":"67","author":"Kimball","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib75","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaad.2008.09.022","article-title":"The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003\u20132004","volume":"60","author":"Kurd","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib76","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000481882","article-title":"Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies","volume":"233","author":"Kyriakou","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2021.02.743_bib161","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis-results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2021.02.743_bib77","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaad.2020.03.031","article-title":"Should biologics for psoriasis be interrupted in the era of COVID-19?","volume":"82","author":"Lebwohl","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib78","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.02.743_bib162","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)","volume":"79","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib79","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib163","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.02.743_bib80","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/CIRCULATIONAHA.116.026859","article-title":"Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study","volume":"136","author":"Lerman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jid.2021.02.743_bib81","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2021.02.743_bib82","doi-asserted-by":"crossref","first-page":"e1162","DOI":"10.1161\/CIR.0000000000000638","article-title":"Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology","volume":"139","author":"Lloyd-Jones","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jid.2021.02.743_bib83","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/jdv.12232","article-title":"Psoriasis and dyslipidemia: a population-based study analyzing the National Health and Nutrition Examination Survey (NHANES)","volume":"28","author":"Ma","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.02.743_bib84","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaad.2005.11.1079","article-title":"Psoriasis is associated with lipid abnormalities at the onset of skin disease","volume":"54","author":"Mallbris","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib85","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/jamadermatol.2016.2907","article-title":"Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes","volume":"152","author":"Mansouri","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib86","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.02.743_bib87","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A\u00a0head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2021.02.743_bib88","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jid.2021.02.743_bib89","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1479-5876-11-194","article-title":"Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis","volume":"11","author":"Mehta","year":"2013","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jid.2021.02.743_bib90","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2012.06.068","article-title":"Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis","volume":"224","author":"Mehta","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jid.2021.02.743_bib91","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jid.2021.02.743_bib92","doi-asserted-by":"crossref","first-page":"775.e1","DOI":"10.1016\/j.amjmed.2011.03.028","article-title":"Attributable risk estimate of severe psoriasis on major cardiovascular events","volume":"124","author":"Mehta","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jid.2021.02.743_bib93","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2011.119","article-title":"Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET\/CT): a pilot study","volume":"147","author":"Mehta","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib164","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib94","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib95","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib96","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/jdv.12761","article-title":"Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study","volume":"29","author":"Mrowietz","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.02.743_bib97","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2017.05.018","article-title":"IL-17A causes depression-like symptoms via NF\u03baB and p38MAPK signaling pathways in mice: implications for psoriasis associated depression","volume":"97","author":"Nadeem","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.jid.2021.02.743_bib98","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1161\/ATVBAHA.115.306460","article-title":"Severity of Psoriasis Associates with aortic vascular inflammation detected by FDG PET\/CT and neutrophil activation in a prospective observational study","volume":"35","author":"Naik","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jid.2021.02.743_bib99","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1111\/jdv.16441","article-title":"Functional and anatomical brain connectivity in psoriasis patients and healthy controls: a pilot brain imaging study after exposure to mentally-induced itch","volume":"34","author":"Najafi","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.02.743_bib100","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jid.2017.12.029","article-title":"The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch","volume":"138","author":"Nattkemper","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib101","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib102","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jid.2017.07.841","article-title":"Objective measures of psoriasis severity predict mortality: a prospective population-based cohort study [published correction appears in J Invest Dermatol 2018;138:998]","volume":"138","author":"Noe","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib103","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.gastro.2020.03.062","article-title":"Uneventful course in patients with inflammatory bowel disease during the severe acute respiratory syndrome coronavirus 2 outbreak in Northern Italy","volume":"159","author":"Norsa","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jid.2021.02.743_bib104","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/jid.2015.218","article-title":"Psoriasis and cardiovascular risk: strength in numbers part 3","volume":"135","author":"Ogdie","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib105","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41577-020-0328-z","article-title":"COVID-19: a case for inhibiting IL-17?","volume":"20","author":"Pacha","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2021.02.743_bib165","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib166","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.02.743_bib106","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib167","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib168","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2021.02.743_bib107","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaad.2020.01.056","article-title":"Serlopitant for psoriatic pruritus: a phase 2 randomized, double-blind, placebo-controlled clinical trial","volume":"82","author":"Pariser","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib108","article-title":"Causal relationship and shared genetic loci between psoriasis and type 2 diabetes through trans-disease meta-analysis [e-pub ahead of print]","author":"Patrick","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib109","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib110","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jamadermatol.2018.2127","article-title":"Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: results from the NutriNet-sante cohort","volume":"154","author":"Phan","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib169","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.02.743_bib170","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib171","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.02.743_bib111","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.02.743_bib112","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease [published correction appears in Lancet 2020;395:1906]","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.02.743_bib113","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.02.743_bib114","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jcmg.2017.08.014","article-title":"Visceral adiposity in psoriasis is associated with vascular inflammation by 18F-Fluorodeoxyglucose Positron-Emission Tomography\/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study","volume":"11","author":"Rivers","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jid.2021.02.743_bib115","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib116","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jid.2021.02.743_bib117","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.16736","article-title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","volume":"179","author":"Ryan","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib118","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fimmu.2018.01234","article-title":"Potential immunological links between psoriasis and cardiovascular disease","volume":"9","author":"Sajja","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2021.02.743_bib119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neubiorev.2018.01.009","article-title":"The vicious cycle of itch and anxiety","volume":"87","author":"Sanders","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jid.2021.02.743_bib172","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220868","article-title":"Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response","volume":"14","author":"Sawyer","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2021.02.743_bib121","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/10253890500504557","article-title":"Role of stress, corticotrophin releasing factor (CRF) and amygdala plasticity in chronic anxiety","volume":"8","author":"Shekhar","year":"2005","journal-title":"Stress"},{"key":"10.1016\/j.jid.2021.02.743_bib122","first-page":"667","article-title":"Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy","volume":"164","author":"Shibata","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib123","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1038\/ncomms8687","article-title":"Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from \u03b3\u03b4-T cells","volume":"6","author":"Shibata","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2021.02.743_bib124","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/bjd.16116","article-title":"Psychological stress and psoriasis: a systematic review and meta-analysis","volume":"178","author":"Snast","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib125","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1016\/j.jid.2017.07.822","article-title":"Obesity, waist circumference, weight change, and risk of incident psoriasis: prospective data from the HUNT study","volume":"137","author":"Snekvik","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib126","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1161\/CIRCRESAHA.118.313608","article-title":"Association between oxidation-modified lipoproteins and coronary plaque in psoriasis","volume":"123","author":"Sorokin","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jid.2021.02.743_bib127","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.atherosclerosis.2014.11.004","article-title":"Association between psoriasis and coronary calcium score","volume":"237","author":"Staniak","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jid.2021.02.743_bib128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40744-017-0070-6","article-title":"Comparative effectiveness of adalimumab versus secukinumab for the treatment of psoriatic arthritis: a matching-adjusted indirect comparison","volume":"4","author":"Strand","year":"2017","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jid.2021.02.743_bib129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjd.17149","article-title":"Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials","volume":"180","author":"Strober","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib130","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.02.743_bib131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacbts.2018.10.008","article-title":"Neutrophil subsets, platelets, and vascular disease in psoriasis","volume":"4","author":"Teague","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jid.2021.02.743_bib132","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/joim.12093","article-title":"Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: a population-based cohort study","volume":"274","author":"Thorslund","year":"2013","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jid.2021.02.743_bib133","doi-asserted-by":"crossref","first-page":"e13827","DOI":"10.1111\/dth.13827","article-title":"Psychodermatological mechanisms of psoriasis","volume":"33","author":"Torales","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2021.02.743_bib134","doi-asserted-by":"crossref","first-page":"7304345","DOI":"10.1155\/2019\/7304345","article-title":"The influence of FTO polymorphism rs9939609 on obesity, some clinical features, and disturbance of carbohydrate metabolism in patients with psoriasis","volume":"2019","author":"Tupikowska-Marzec","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jid.2021.02.743_bib173","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.02.743_bib135","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/39335","article-title":"Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function","volume":"389","author":"Uysal","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jid.2021.02.743_bib136","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41467-018-07911-6","article-title":"ROR\u03b3t inhibition selectively targets IL-17 producing iNKT and \u03b3\u03b4-T cells enriched in spondyloarthritis patients","volume":"10","author":"Venken","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2021.02.743_bib137","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ced.12699","article-title":"Effect of inhibition of interleukin-12\/23 by ustekinumab on the expression of leptin and leptin receptor in human THP-1 macrophages","volume":"41","author":"Voloshyna","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib138","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib139","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaad.2017.10.050","article-title":"Psoriasis and the risk of diabetes: a prospective population-based cohort study","volume":"78","author":"Wan","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2016.07.042","article-title":"Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus methotrexate","volume":"76","author":"Wu","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib141","first-page":"932","article-title":"Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both","volume":"13","author":"Wu","year":"2014","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib142","first-page":"899","article-title":"Association between the type and length\u00a0of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"12","author":"Wu","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib143","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib144","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-020-02208-w","article-title":"Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis","volume":"22","author":"Yin","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2021.02.743_bib145","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jid.2016.03.035","article-title":"Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis","volume":"136","author":"Yiu","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib146","first-page":"1645","article-title":"Ixekizumab improved patient-reported genital psoriasis symptoms and impact of symptoms on sexual activity vs placebo in a randomized, double-blind study","volume":"15","author":"Yosipovitch","year":"2018","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.jid.2021.02.743_bib147","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s13555-018-0267-9","article-title":"Impact of ixekizumab treatment on itch and psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis: an integrated analysis of two phase III randomized studies","volume":"8","author":"Yosipovitch","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2021.02.743_bib148","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2340\/00015555-3195","article-title":"Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials","volume":"99","author":"Yosipovitch","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2021.02.743_bib149","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/1346-8138.12859","article-title":"Subclinical systemic and vascular inflammation detected by 18 F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with mild psoriasis","volume":"42","author":"Youn","year":"2015","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jid.2021.02.743_bib150","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1126\/science.aak9748","article-title":"Molecular and neural basis of contagious itch behavior in mice","volume":"355","author":"Yu","year":"2017","journal-title":"Science"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21010071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21010071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:47:22Z","timestamp":1762206442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21010071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":173,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0022202X21010071"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.02.743","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Frontiers in Psoriatic Disease Research,\u00a0Part II: Comorbidities and Targeted Therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.02.743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}